A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression

被引：0
|
作者：
Siegfried Kasper
Nicole Praschak-Rieder
Johannes Tauscher
Rainer Wolf
机构：
[1] University of Vienna,Department of General Psychiatry
来源：
Drug Safety | 1997年 / 17卷
关键词：
Adis International Limited; Amitriptyline; Sexual Dysfunction; Mirtazapine; Clomipramine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mirtazapine is the first of a new class of antidepressants, the noradrenergic and specific serotonergic antidepressants (NaSSA). Its antidepressant effect appears to be related to its dual enhancement of central noradrenergic and serotonin 5-HT1 receptor-mediated serotonergic neurotransmission.
引用
收藏
页码：251 / 264
页数：13
相关论文
共 50 条
  • [1] A risk-benefit assessment of mirtazapine in the treatment of depression
    Kasper, S
    PraschakRieder, N
    Tauscher, J
    Wolf, R
    DRUG SAFETY, 1997, 17 (04) : 251 - 264
  • [2] A risk-benefit assessment of mirtazapine in the treatment of depression (vol 17, pg 251, 1997)
    Kasper, S
    Praschak-Rieder, N
    Tauscher, J
    Wolf, R
    DRUG SAFETY, 1998, 18 (02) : 123 - 123
  • [3] A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly
    Aart Jan van der Lely
    Wouter W. de Herder
    Steven W. J. Lamberts
    Drug Safety, 1997, 17 : 317 - 324
  • [4] A risk-benefit assessment of sulpiride in the treatment of schizophrenia
    Mauri, MC
    Bravin, S
    Bitetto, A
    Rudelli, R
    Invernizzi, G
    DRUG SAFETY, 1996, 14 (05) : 288 - 298
  • [5] A risk-benefit assessment of octreotide in the treatment of acromegaly
    vanderLely, AJ
    deHerder, WW
    Lamberts, SWJ
    DRUG SAFETY, 1997, 17 (05) : 317 - 324
  • [6] A RISK-BENEFIT ASSESSMENT OF TEICOPLANIN IN THE TREATMENT OF INFECTIONS
    DELALLA, F
    TRAMARIN, A
    DRUG SAFETY, 1995, 13 (05) : 317 - 328
  • [7] A Risk-Benefit Assessment of Pharmacotherapies for Clinical Depression in Children and Adolescents
    Johanne Renaud
    David Axelson
    Boris Birmaher
    Drug Safety, 1999, 20 : 59 - 75
  • [8] A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents
    Renaud, J
    Axelson, D
    Birmaher, B
    DRUG SAFETY, 1999, 20 (01) : 59 - 75
  • [9] A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension
    Louise M. Burrell
    Drug Safety, 1997, 16 : 56 - 65
  • [10] A risk-benefit assessment of agents used in the treatment of scabies
    Elgart, ML
    DRUG SAFETY, 1996, 14 (06) : 386 - 393
12345